Release date：2019-12-05
Regarding the statement recently issued by Diaclone Life Sciences Co., Ltd. (hereinafter referred to as "Diaclone Life Sciences") through its official website and WeChat public account, our company hereby makes the following solemn statement:
Our company respects the intellectual property rights of any third party. After receiving the litigation materials forwarded by the court, our company has entrusted professionals to conduct analysis and comparison, and after review by a third-party laboratory, we believe that our products do not fall within the scope of patent protection and do not constitute infringement.
Our company has entrusted a professional organization to search and analyze, and believes that the claims of the involved patent are common knowledge to those skilled in the art and lack creativity. On November 8, 2019, our company submitted an invalidation request to the National Intellectual Property Administration, and the National Intellectual Property Administration officially accepted the case on November 19, 2019.
Diaclone Life Sciences has misleadingly disseminated and described the unresolved judicial matters, which has seriously damaged our company's business reputation. Our company has entrusted lawyers to collect and notarize relevant evidence and will pursue its corresponding legal responsibilities through legal means.
Our company respects the intellectual property rights of others and hopes to create a harmonious and orderly relationship of benign competition with other companies in the same industry. However, our company will firmly defend its legitimate rights and interests against any false reports or misleading descriptions.
We thank our long-term customers for their continued support and love, and our company will always adhere to the principle of people-oriented and integrity-based business to provide better products and services to our new and old customers!
Baiding Healthcare (BDH) Group
December 5, 2019
